Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin Deficiency
This year’s International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key independent symposiums by Clinical Care Options attracting attention from hepatology and gastroenterology professionals worldwide. Each session focuses on cutting-edge approaches and therapies poised to reshape patient care in complex liver conditions, operating as independent symposiums to ensure unbiased and comprehensive educational experiences. The symposium are available to clinicians both live in person and live online.
Itching for More: Improving Care of Pruritus in PBC
On Monday November 18, 12:30pm -2:00pm Pacific, experts gather to address a critical symptom affecting patients with Primary Biliary Cholangitis (PBC): pruritus. Dr. Stuart C. Gordon and Dr. Marlyn J. Mayo lead the session, “Itching for More: Improving Care of Pruritus in PBC,” discussing the profound impact of pruritus on patient quality of life and the latest therapeutic advances. Supported by an educational grant from GlaxoSmithKline, the symposium emphasizes a multidisciplinary approach, integrating patient perspectives with expert insights from healthcare providers.
Key highlights include:
- Assessment techniques to measure the severity of pruritus.
- Comprehensive treatment plans combining pharmacologic and non-pharmacologic interventions.
- Emerging therapies that offer new hope for managing this debilitating symptom.
This session is particularly beneficial for physicians, including hepatologists and gastroenterologists, involved in the care of patients with PBC, offering up to 1.50 AMA PRA Category 1 Credits™ for attendees.
Alpha-1 Antitrypsin Deficiency: Are You Overlooking a Leading Genetic Culprit in Liver Disease?
On Tuesday November 19th at 12:30 pm – 2:00pm Pacific, the focus shifts to Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition often missed in the differential diagnosis of liver disease. This symposium features a panel including Dr. Mark Brantly, Dr. Virginia Clark, and Dr. Pavel Strnad, who explore the pathophysiology, diagnosis, and management of liver disease associated with AATD. Supported by an educational grant from Takeda Development Center Americas, Inc., the session underscores the necessity for heightened awareness and improved diagnostic strategies to manage this underdiagnosed condition effectively.
Participants are encouraged to:
- Recognize the clinical manifestations of AATD-related liver disease.
- Utilize recommended diagnostic procedures for accurate detection.
- Explore investigational therapies that hold promise for future treatment options.
This symposium caters to a broad audience, including hepatologists, gastroenterologists, and pulmonologists, and provides up to 1.0 AMA PRA Category 1 Credits™.
Forward-Looking Initiatives
Both sessions are available in the Sandiego Convention Center and exemplify Clinical Care Options commitment to advancing liver disease treatment through collaborative learning and patient-centered care. These independent discussions not only highlight the latest scientific advancements but also reinforce the importance of continued education and patient engagement in improving outcomes in hepatology.
For more information on future events and educational opportunities, visit Clinical Care Options
Itching for More: Improving Care of Pruritus in PBC
Alpha-1 Antitrypsin Deficiency: Are You Overlooking a Leading Genetic Culprit in Liver Disease?